Followers | 82 |
Posts | 5373 |
Boards Moderated | 0 |
Alias Born | 11/29/2016 |
Wednesday, December 13, 2017 9:04:16 PM
ViaDerma Investor Relations <info@viadermalicensing.com>
Today, 7:29 PMYou
K'''
Let me clairify the breakdown of the VDRM/Biogenx deal. The 5% is a licensing fee to VDRM off the top. After that the profits are split 50%-50%. So net split is ViaDerma 55% and Biogenx 45%. That is only for sales generated by Biogenx. As for all sales generated by VDRM have different arrangements giving VDRM as much 75% share of sales. The 25% ownership is really meaningless because Biogenx ONLY receives money for Biogenx sales. They make nothing on all non-Biogenx generated sales.
I hope this clarifies.
---
ViaDerma Investor Relations
310-734-6111
On 2017-12-13 19:14, K== M======= wrote:
>
> How could THE DR. TAKE SHAREHOLDER MONEY to start up production and leave us only 5%. Biogenx should be a subsidiary to Viaderma.
>
>
>
> Sounds like a scam to us shareholders and it will be explored more in depth. I own 14 million shares.
>
>
>
>
> Biogenx, Inc. is minority owned (25%) by the Company's President, Dr. Chris Otiko. Did we get scammed or what?
>
>
>
> K=== M]]]]]]]]
>
> Englewood FL.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM